{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:12:51Z","timestamp":1790863971355,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institutes for Health Research","award":["FDN-148412"],"award-info":[{"award-number":["FDN-148412"]}]},{"name":"University of British Columbia Four Year Doctoral Fellowship","award":["FDN-148412"],"award-info":[{"award-number":["FDN-148412"]}]},{"name":"Canada Research Chair","award":["FDN-148412"],"award-info":[{"award-number":["FDN-148412"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Access to hepatitis C (HCV) testing and treatment is still limited globally. To address this, the Government of Rwanda launched a voluntary mass screening and treatment campaign in 2017. We studied the progression of patients through the cascade of HCV care during this campaign. We conducted a retrospective cohort study and included all patients screened at 46 hospitals between April 2017 and October 2019. We used hierarchical logistic regression to assess factors associated with HCV positivity, gaps in care, and treatment failure. A total of 860,801 people attended the mass screening during the study period. Some 5.7% tested positive for anti-HCV, and 2.9% were confirmed positive. Of those who were confirmed positive, 52% initiated treatment, and 72% of those initiated treatment, completed treatment and returned for assessment 12 weeks afterward. The cure rate was 88%. HCV positivity was associated with age, socio-economic status, sex, marital status, and HIV coinfection. Treatment failure was associated with cirrhosis, baseline viral load, and a family history of HCV. Our results suggest that future HCV screening and testing interventions in Rwanda and other similar settings should target high-risk groups. High dropout rates suggest that more effort should be put into patient follow-up to increase adherence to care.<\/jats:p>","DOI":"10.3390\/v15030661","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T03:03:48Z","timestamp":1677639828000},"page":"661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017\u20132019 Mass Screening and Treatment Campaign"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-5841","authenticated-orcid":false,"given":"Marie Paul","family":"Nisingizwe","sequence":"first","affiliation":[{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"},{"name":"School of Population and Public Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-8844","authenticated-orcid":false,"given":"Jean Damascene","family":"Makuza","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"},{"name":"Rwanda Biomedical Centre, Kigali 7162, Rwanda"},{"name":"British Columbia, Center for Disease Control, Vancouver, BC V5Z 4R4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-719X","authenticated-orcid":false,"given":"Naveed Z.","family":"Janjua","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"},{"name":"British Columbia, Center for Disease Control, Vancouver, BC V5Z 4R4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Hedt-Gauthier","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Global Health and Social Medicine, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvier","family":"Serumondo","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Centre, Kigali 7162, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Remera","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Centre, Kigali 7162, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"},{"name":"School of Population and Public Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15403\/jgld-1284","article-title":"Benefits of Curing Hepatitis C Infection","volume":"23","author":"Marinho","year":"2014","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Groeger","year":"2013","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(02)00264-5","article-title":"Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa","volume":"2","author":"Madhava","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40273-013-0073-2","article-title":"Protease inhibitors for hepatitis C: Economic implications","volume":"31","author":"Turner","year":"2013","journal-title":"PharmacoEconomics"},{"key":"ref_5","unstructured":"(2022, December 19). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789240027077."},{"key":"ref_6","unstructured":"World Health Organization (2017). Global Hepatitis Report, World Health Organization."},{"key":"ref_7","unstructured":"World Health Organization (2022, December 19). The Top 10 Causes of Death, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vhri.2013.09.002","article-title":"Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden","volume":"3","author":"Thongsawat","year":"2014","journal-title":"Value Health Reg. Issues"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cncr.29855","article-title":"Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis","volume":"122","author":"Tapper","year":"2016","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.13316","article-title":"Economic burden of hepatitis C in Egypt: The future impact of highly effective therapies","volume":"42","author":"Estes","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/MEG.0b013e3283566658","article-title":"Resource use and cost of hepatitis C-related care","volume":"24","author":"Nevens","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/jgh.13223","article-title":"Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia","volume":"31","author":"Hellard","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2014.09.019","article-title":"Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings","volume":"61","author":"Ford","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gupta, N., Kabahizi, J., Mukabatsinda, C., Walker, T.D., Musabeyezu, E., Kiromera, A., Van Nuil, J.I., Steiner, K., Mukherjee, J., and Nsanzimana, S. (2017). \u201cWaiting for DAAs\u201d: A retrospective chart review of patients with untreated hepatitis C in Rwanda. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174148"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofu065","DOI":"10.1093\/ofid\/ofu065","article-title":"Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention","volume":"1","author":"Layden","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12992-017-0297-6","article-title":"Access to medicines and hepatitis C in Africa: Can tiered pricing and voluntary licencing assure universal access, health equity and fairness?","volume":"13","author":"Assefa","year":"2017","journal-title":"Glob. Health"},{"key":"ref_17","first-page":"5","article-title":"Increasing Access to Hepatitis C Treatment in Rwanda: The Promise of Rwanda: Existing HIV Infrastructure","volume":"3","author":"Nsanzimana","year":"2015","journal-title":"J. Infect. Dis. Ther."},{"key":"ref_18","unstructured":"(2022, July 26). How Rwanda Is Eliminating Hepatitis C and What Canada Can Learn from Its Successes. Available online: https:\/\/blog.catie.ca\/2021\/11\/18\/how-rwanda-is-eliminating-hepatitis-c-and-what-canada-can-learn-from-its-successes\/."},{"key":"ref_19","unstructured":"(2019, February 07). WHO|Combating Hepatitis B and C to Reach Elimination by 2030. Available online: http:\/\/www.who.int\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S2468-1253(18)30089-X","article-title":"Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda","volume":"3","author":"Gupta","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa","volume":"70","author":"Umutesi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_22","first-page":"E674","article-title":"The hepatitis C virus cascade of care in a Quebec provincial prison: A retrospective cohort study","volume":"7","author":"Kronfli","year":"2019","journal-title":"Can. Med. Assoc. Open Access J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/jvh.13574","article-title":"Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis","volume":"28","author":"Yousafzai","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_24","first-page":"44","article-title":"Hepatitis C virus (HCV) infection in Africa: A review","volume":"14","author":"Karoney","year":"2013","journal-title":"Pan Afr. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kamali, I., Shumbusho, F., Barnhart, D.A., Nyirahabihirwe, F., Gakuru, J.P., Dusingizimana, W., Nizeyumuremyi, E., Habinshuti, P., Walker, S., and Makuza, J.D. (2022). Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: A retrospective cohort study. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07271-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(14)60574-2","article-title":"Thierry Nyatanyi 20 years on: Investing in life","volume":"384","author":"Binagwaho","year":"2014","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S0618-8278(19)30658-9","article-title":"THU-411-Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda","volume":"70","author":"Nsanzimana","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_28","unstructured":"(2022, December 19). Universal Health Coverage: How Rwanda Is Moving forward with Healthcare for All|Innovations in Healthcare. Available online: https:\/\/www.innovationsinhealthcare.org\/universal-health-coverage-how-rwanda-is-moving-forward-with-healthcare-for-all\/."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Makuza, J.D., Rwema, J.O.T., Ntihabose, C.K., Dushimiyimana, D., Umutesi, J., Nisingizwe, M.P., Serumondo, J., Semakula, M., Riedel, D.J., and Nsanzimana, S. (2019). Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4013-4"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Umutesi, J., Simmons, B., Makuza, J.D., Dushimiyimana, D., Mbituyumuremyi, A., Uwimana, J.M., Ford, N., Mills, E.J., and Nsanzimana, S. (2017). Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2422-9"},{"key":"ref_31","first-page":"273","article-title":"The SD BIOLINE Rapid Test for Detection of Antibodies to HCV among High-Risk Patients","volume":"30","author":"Arteaga","year":"2015","journal-title":"Rev. Colomb. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","article-title":"Hepatitis C in sub-Saharan Africa: The current status and recommendations for achieving elimination by 2030","volume":"2","author":"Sonderup","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ezeanya, C. (2022, December 19). Home-Grown and Grassroots-Based Strategies for Determining Inequality towards Policy Action: Rwanda\u2019s Ubudehe Approach in Perspective. Available online: https:\/\/www.wider.unu.edu\/sites\/default\/files\/wp2015-008.pdf.","DOI":"10.35188\/UNU-WIDER\/2015\/893-3"},{"key":"ref_34","unstructured":"Song, M., Zhou, X., Pazaris, M., and Spiegelman, D. (2022, December 19). The Missing Covariate Indicator Method Is Nearly Valid Almost Always 2021. Available online: https:\/\/doi.org\/10.48550\/arXiv.2111.00138."},{"key":"ref_35","unstructured":"(2022, December 19). Rwanda Population (2023)\u2014Worldometer. Available online: https:\/\/www.worldometers.info\/world-population\/rwanda-population\/."},{"key":"ref_36","first-page":"245","article-title":"HIV incidence and prevalence among adults aged 15\u201364 years in Rwanda: Results from the Rwanda Population-based HIV Impact Assessment (RPHIA) and District-level Modeling, 2019","volume":"116","author":"Nsanzimana","year":"2022","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Makuza, J.D., Liu, C.Y., Ntihabose, C.K., Dushimiyimana, D., Umuraza, S., Nisingizwe, M.P., Umutesi, J., Serumondo, J., Mugeni, S.D., and Semakula, M. (2019). Risk factors for viral hepatitis C infection in Rwanda: Results from a nationwide screening program. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4322-7"},{"key":"ref_38","unstructured":"(2022, December 19). 2005-2020 Rates of Acute Hepatitis C Cases by Age|Center for Disease Control. 10 October 2022, Available online: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c\/figure-3.4.htm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e029743","DOI":"10.1136\/bmjopen-2019-029743","article-title":"Screening a nation for hepatitis C virus elimination: A cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population","volume":"9","author":"Umutesi","year":"2019","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(02)09284-X","article-title":"Unsterile injections and emergence of human pathogens","volume":"359","author":"Hutin","year":"2002","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/jvh.12966","article-title":"The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania","volume":"25","author":"Mohamed","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.21101\/cejph.a3628","article-title":"Risk factors of hepatitis C infection among Egyptian blood donors","volume":"19","author":"Awadalla","year":"2011","journal-title":"Cent. Eur. J. Public Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.trstmh.2008.04.011","article-title":"Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt","volume":"102","author":"Saleh","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/bsp.2014.0032","article-title":"Health Inequalities and Infectious Disease Epidemics: A Challenge for Global Health Security","volume":"12","author":"Quinn","year":"2014","journal-title":"Biosecurity Bioterrorism Biodefense Strategy Pract. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural History and Management of Hepatitis C: Does Sex Play a Role?","volume":"209","author":"Baden","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Baha, W., Foullous, A., Dersi, N., They-they, T.P., Alaoui, K.E., Nourichafi, N., Oukkache, B., Lazar, F., Benjelloun, S., and Ennaji, M.M. (2013). Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health, 13.","DOI":"10.1186\/1471-2458-13-50"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Serumondo, J., Penkunas, M.J., Niyikora, J., Ngwije, A., Kiromera, A., Musabeyezu, E., Umutesi, J., Umuraza, S., Musengimana, G., and Nsanzimana, S. (2020). Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: A qualitative exploration of barriers and facilitators. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-09000-0"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(18)30320-9","article-title":"Direct-acting antiviral treatment in sub-Saharan Africa: A prospective trial of Ledipasvir\/Sofosbuvir for chronic Hepatitis C infection in Rwanda (the SHARED study)","volume":"68","author":"Gupta","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S2468-1253(21)00399-X","article-title":"Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): A single-arm trial","volume":"7","author":"Gupta","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2468-1253(21)00465-9","article-title":"Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa","volume":"7","author":"Opio","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e3300","DOI":"10.1093\/cid\/ciaa701","article-title":"Effectiveness of Direct-Acting Antivirals for the treatment of chronic hepatitis C in Rwanda: A retrospective study","volume":"73","author":"Nsanzimana","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jceh.2018.01.001","article-title":"Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa","volume":"8","author":"Luma","year":"2018","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","article-title":"The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)","volume":"12","author":"Janjua","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.puhe.2017.11.014","article-title":"Association between non-communicable disease multimorbidity and health care utilization in a middle-income country: Population-based study","volume":"155","author":"Jankovic","year":"2018","journal-title":"Public Health"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/01410768211051715","article-title":"Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland","volume":"115","author":"Agrawal","year":"2022","journal-title":"J. R. Soc. Med."},{"key":"ref_58","unstructured":"(2022, July 21). Screening and Treatment Program to Eliminate Hepatitis C in Egypt|NEJM. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMsr1912628."},{"key":"ref_59","unstructured":"(2022, November 01). World Bank Poverty Headcount Ratio at National Poverty Lines (% of population)\u2014Rwanda|Data. Available online: https:\/\/data.worldbank.org\/indicator\/SI.POV.NAHC?locations=RW."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14745\/ccdr.v44i78a02","article-title":"Awareness and knowledge of hepatitis C among health care providers and the public: A scoping review","volume":"44","author":"Ha","year":"2018","journal-title":"Can. Commun. Dis. Rep."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:47Z","timestamp":1760121887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["v15030661"],"URL":"https:\/\/doi.org\/10.3390\/v15030661","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}